{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:04:49Z","timestamp":1787497489322,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00198-022-06386-y","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T06:57:41Z","timestamp":1648796261000},"page":"1807-1813","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2426-1024","authenticated-orcid":false,"given":"K.","family":"Ebina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Etani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Nagayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kashii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Miyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kunugiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1408-7851","authenticated-orcid":false,"given":"M.","family":"Hirao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Takami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Goshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8964-4229","authenticated-orcid":false,"given":"K.","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"key":"6386_CR1","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/joim.12873","volume":"285","author":"M Lorentzon","year":"2019","unstructured":"Lorentzon M (2019) Treating osteoporosis to prevent fractures: current concepts and future developments. J Intern Med 285:381\u2013394","journal-title":"J Intern Med"},{"key":"6386_CR2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420","journal-title":"N Engl J Med"},{"key":"6386_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","volume":"96","author":"J Delgado-Calle","year":"2017","unstructured":"Delgado-Calle J, Sato AY, Bellido T (2017) Role and mechanism of action of sclerostin in bone. Bone 96:29\u201337","journal-title":"Bone"},{"key":"6386_CR4","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"6386_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3622","volume":"34","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, Gielen E, Milmont CE, Libanati C, Grauer A (2019) One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res 34:419\u2013428","journal-title":"J Bone Miner Res"},{"key":"6386_CR6","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386:1147\u20131155","journal-title":"Lancet"},{"key":"6386_CR7","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/jbmr.1853","volume":"28","author":"F Cosman","year":"2013","unstructured":"Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, Krege JH (2013) Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Miner Res 28:1328\u20131336","journal-title":"J Bone Miner Res"},{"key":"6386_CR8","doi-asserted-by":"publisher","first-page":"115574","DOI":"10.1016\/j.bone.2020.115574","volume":"140","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hirao M, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S, Miyama A, Nakaya H, Kunugiza Y, Okamura G, Etani Y, Takami K, Goshima A, Nakata K (2020) Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone 140:115574","journal-title":"Bone"},{"key":"6386_CR9","doi-asserted-by":"publisher","first-page":"105219","DOI":"10.1016\/j.jbspin.2021.105219","volume":"88","author":"K Ebina","year":"2021","unstructured":"Ebina K, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S, Miyama A, Nakaya H, Kunugiza Y, Hirao M, Okamura G, Etani Y, Takami K, Goshima A, Miura T, Nakata K, Okada S (2021) Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis. Joint Bone Spine 88:105219","journal-title":"Joint Bone Spine"},{"key":"6386_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11657-012-0109-9","volume":"7","author":"H Orimo","year":"2012","unstructured":"Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N, Ohta H, Shiraki M, Sugimoto T, Suzuki T, Soen S, Nishizawa Y, Hagino H, Fukunaga M, Fujiwara S (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis\u2013executive summary. Arch Osteoporos 7:3\u201320","journal-title":"Arch Osteoporos"},{"key":"6386_CR11","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137\u20131148","journal-title":"J Bone Miner Res"},{"key":"6386_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jocd.2016.03.003","volume":"19","author":"EM Lewiecki","year":"2016","unstructured":"Lewiecki EM, Binkley N, Morgan SL, Shuhart CR, Camargos BM, Carey JJ, Gordon CM, Jankowski LG, Lee JK, Leslie WD, International Society for Clinical Densitometry (2016) Best practices for dual-energy X-ray absorptiometry measurement and reporting: International Society for Clinical Densitometry guidance. J Clin Densitom 19:127\u2013140","journal-title":"J Clin Densitom"},{"key":"6386_CR13","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s00198-018-4492-y","volume":"29","author":"K Ebina","year":"2018","unstructured":"Ebina K, Hirao M, Hashimoto J, Matsuoka H, Iwahashi T, Chijimatsu R, Etani Y, Okamura G, Miyama A, Yoshikawa H (2018) Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naive rheumatoid arthritis. Osteoporos Int 29:1627\u20131636","journal-title":"Osteoporos Int"},{"key":"6386_CR14","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1359\/JBMR.050403","volume":"20","author":"A Nenonen","year":"2005","unstructured":"Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimaki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Sievanen H, Vuori I, Vaananen HK, Halleen JM (2005) Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20:1804\u20131812","journal-title":"J Bone Miner Res"},{"key":"6386_CR15","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s00774-017-0861-4","volume":"36","author":"K Ebina","year":"2018","unstructured":"Ebina K, Hirao M, Hashimoto J, Hagihara K, Kashii M, Kitaguchi K, Matsuoka H, Iwahashi T, Chijimatsu R, Yoshikawa H (2018) Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis. J Bone Miner Metab 36:478\u2013487","journal-title":"J Bone Miner Metab"},{"key":"6386_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"6386_CR17","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00774-020-01147-5","volume":"39","author":"A Miyauchi","year":"2021","unstructured":"Miyauchi A, Hamaya E, Yang W, Nishi K, Libanati C, Tolman C, Shimauchi J (2021) Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial. J Bone Miner Metab 39:278\u2013288","journal-title":"J Bone Miner Metab"},{"key":"6386_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00774-015-0731-x","volume":"35","author":"K Ebina","year":"2017","unstructured":"Ebina K, Hashimoto J, Kashii M, Hirao M, Kaneshiro S, Noguchi T, Tsukamoto Y, Yoshikawa H (2017) The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. J Bone Miner Metab 35:91\u201398","journal-title":"J Bone Miner Metab"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06386-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-022-06386-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06386-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T13:09:48Z","timestamp":1663852188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-022-06386-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["6386"],"URL":"https:\/\/doi.org\/10.1007\/s00198-022-06386-y","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"assertion":[{"value":"8 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"KE is affiliated with the Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, which is supported by Taisho. KE and MH have received research grants from Amgen, Asahi-Kasei, Astellas, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, and Ono. KE has received payments for lectures from Amgen, Asahi-Kasei, Astellas, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Ono, and Pfizer. HT has received a research grant from Chugai and has received payments for lectures from Asahi-Kasei, Astellas, Chugai, Eisai, Eli Lilly, and Pfizer. YN has received payments for lectures from Asahi-Kasei, Astellas, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, and Ono. MK has received payments for lectures from Asahi-Kasei and Astellas. KN has received a research grant from Astellas and supervises the Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, which is supported by Taisho. YE, AM, YK, GO, TN, KT, AG, TM, YF, TK, and SO declare that they have no conflicts of interest. The funders had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}